Trial Profile
A Phase I Study Of BAY 38-3441 Given As A Short Infusion Daily For Five Days Every Three Weeks.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2009
Price :
$35
*
At a glance
- Drugs Afeletecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Feb 2006 New trial record.